AR050937A1 - Composicion para administracion a traves de la mucosa y metodo para aumentar la absorcion a traves de la mucosa - Google Patents

Composicion para administracion a traves de la mucosa y metodo para aumentar la absorcion a traves de la mucosa

Info

Publication number
AR050937A1
AR050937A1 ARP050103852A ARP050103852A AR050937A1 AR 050937 A1 AR050937 A1 AR 050937A1 AR P050103852 A ARP050103852 A AR P050103852A AR P050103852 A ARP050103852 A AR P050103852A AR 050937 A1 AR050937 A1 AR 050937A1
Authority
AR
Argentina
Prior art keywords
mucosa
administration
composition
absorption
increase
Prior art date
Application number
ARP050103852A
Other languages
English (en)
Inventor
Akira Yamamoto
Keigo Yamada
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR050937A1 publication Critical patent/AR050937A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion para administracion a través de la mucosa que permita que los péptidos y las proteínas farmacologicamente activos sean eficientemente absorbidos a través de la mucosa, tal como la mucosa pulmonar, nasal, oral, vaginal, gástrica, gastrointestinal o similares. Una composicion para administracion a través de la mucosa se prepara por adicion de i) al menos un miembro seleccionado en el grupo constituido por péptidos y por proteínas que tienen una actividad farmacologica; y ii) al menos un miembro seleccionado en el grupo constituido por oligosacáridos de quitosán que tienen un grado de polimerizacion que oscila entre 2 y 20, sus derivados, glucosamina y sus sales.
ARP050103852A 2004-09-15 2005-09-15 Composicion para administracion a traves de la mucosa y metodo para aumentar la absorcion a traves de la mucosa AR050937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004268891 2004-09-15

Publications (1)

Publication Number Publication Date
AR050937A1 true AR050937A1 (es) 2006-12-06

Family

ID=36059983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103852A AR050937A1 (es) 2004-09-15 2005-09-15 Composicion para administracion a traves de la mucosa y metodo para aumentar la absorcion a traves de la mucosa

Country Status (13)

Country Link
US (1) US20080075691A1 (es)
EP (1) EP1790351A4 (es)
JP (1) JPWO2006030730A1 (es)
KR (1) KR20070057932A (es)
CN (1) CN101018560A (es)
AR (1) AR050937A1 (es)
AU (1) AU2005283512A1 (es)
BR (1) BRPI0515301A (es)
CA (1) CA2577336A1 (es)
MX (1) MX2007003062A (es)
RU (1) RU2007114068A (es)
TW (1) TW200612975A (es)
WO (1) WO2006030730A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682376C (en) * 2007-03-30 2015-10-06 Hirofumi Takeuchi Transpulmonary liposome for controlling drug arrival
PL2253326T3 (pl) * 2008-02-28 2018-09-28 Toray Industries, Inc. Kompozycja farmaceutyczna do podawania przeznosowego
WO2011142484A1 (ja) * 2010-05-14 2011-11-17 株式会社日本触媒 ポリアルキレンイミンを含むウイルス感染症治療薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JPH11116499A (ja) * 1997-10-16 1999-04-27 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有した経口投与用ナノスフェア
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP3041799B1 (ja) * 1998-09-29 2000-05-15 株式会社微生物化学研究所 新規なアジュバント及びそれを用いたワクチン
US6333304B1 (en) * 1999-04-20 2001-12-25 Teresa K. Bath Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
US6773723B1 (en) * 2000-08-30 2004-08-10 Depuy Acromed, Inc. Collagen/polysaccharide bilayer matrix
AU2002210407A1 (en) * 2000-10-27 2002-05-06 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
NO317654B1 (no) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav.
DE102004040243A1 (de) * 2003-08-22 2005-03-17 Heppe, Katja, Dipl.-Biotechnol. Transportsystem auf Chitosanbasis
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution

Also Published As

Publication number Publication date
CN101018560A (zh) 2007-08-15
TWI291874B (es) 2008-01-01
KR20070057932A (ko) 2007-06-07
TW200612975A (en) 2006-05-01
JPWO2006030730A1 (ja) 2008-05-15
EP1790351A4 (en) 2009-11-04
WO2006030730A1 (ja) 2006-03-23
BRPI0515301A (pt) 2008-07-15
RU2007114068A (ru) 2008-10-27
US20080075691A1 (en) 2008-03-27
AU2005283512A1 (en) 2006-03-23
CA2577336A1 (en) 2006-03-23
MX2007003062A (es) 2007-05-21
EP1790351A8 (en) 2007-10-10
EP1790351A1 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
PE20050175A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
NO20045140L (no) Blandinger og fremgangsmate for transmukosal legemiddelavlevering og kryobeskyttelse
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
AR061887A1 (es) Una composicion de vacuna contra el dengue
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
WO2008087323A3 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
AR050937A1 (es) Composicion para administracion a traves de la mucosa y metodo para aumentar la absorcion a traves de la mucosa
PE20080313A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
TN2010000008A1 (en) Oral pharmaceutical solutions containing telbivudine
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
AR053144A1 (es) Composicion farmaceutica solida que comprende telitromicina
DK2252263T3 (da) Galenisk form til oral transmukosal indgivelse af triptaner
AR093275A1 (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
AR053591A1 (es) Utilizacion de la acitromicina para la fabricacion de un medicamento detratamiento de las infecciones oculares

Legal Events

Date Code Title Description
FA Abandonment or withdrawal